More on IQV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $170.67 |
|
|||
| Open | $170.67 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $171.00 | ||||
| Day Low | $162.22 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 3,703,620 | ||||
- Morgan Stanley favors Charles River Over IQVIA in CRO sector reset
- Morgan Stanley Downgrades IQVIA Holdings (IQV) to Equalweight
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
- Form 8-K IQVIA HOLDINGS INC. For: Jun 11
- Morgan Stanley tracks prescription trends for US neurology drugs
- RBC Capital: 'Miebo remains the second-largest Rx DED drug in the US with 22.8% market share'
- Form 8-K IQVIA HOLDINGS INC. For: Jun 04
- IQVIA prices €950 million senior notes due 2033
- IQVIA Announces Pricing of Senior Notes
Entities mentioned with IQV
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Stock Buyback | View Related Stories »
- FDA | View Related Stories »
- Bain Capital | View Related Stories »
- Show More...
